Salvati P, Bianchi G
Arch Int Pharmacodyn Ther. 1985 Apr;274(2):291-304.
Oral administration of a new ergoline derivative (355/1057) produced a sustained arterial hypotension in conscious SHR rats. This effect was inhibited by the centrally acting DA blockers haloperidol and pimozide and by domperidone, a DA antagonist that does not cross the blood brain barrier. On the other hand it was unaffected by alpha- and beta-adrenoceptor blockers or by indomethacin. Moreover, the hypertension induced by 355/1057 in pithed SHR rats was reversed to hypotension when its alpha-adrenoceptor stimulant activity was inhibited by yohimbine. In anesthetized dogs the hypotensive activity of 355/1057 was abolished by pimozide but not by propranolol. In anesthetized cats, pretreatment with haloperidol prevented both the hypotensive activity of 355/1057 and its inhibitory effect on sympathetic nerve activity. These overall data suggest that 355/1057 lowers blood pressure in different species mainly by stimulating peripheral dopamine receptors.
给清醒的自发性高血压大鼠（SHR）口服一种新的麦角灵衍生物（355/1057）会导致持续性动脉低血压。这种效应被中枢作用的多巴胺阻滞剂氟哌啶醇和匹莫齐特以及不穿过血脑屏障的多巴胺拮抗剂多潘立酮所抑制。另一方面，它不受α和β肾上腺素能受体阻滞剂或吲哚美辛的影响。此外，当育亨宾抑制其α肾上腺素能受体刺激活性时，355/1057在脊髓切断的SHR大鼠中诱导的高血压会逆转至低血压。在麻醉犬中，355/1057的降压活性被匹莫齐特消除，但未被普萘洛尔消除。在麻醉猫中，用氟哌啶醇预处理可防止355/1057的降压活性及其对交感神经活动的抑制作用。这些总体数据表明，355/1057在不同物种中主要通过刺激外周多巴胺受体来降低血压。
